Peer-Reviewed Papers

Explore published research on mitochondrial function, cellular energy, (-)-epicatechin, vascular biology, and related metabolic pathways. Browse by specialization below to quickly find the papers most relevant to your interests.

Search Papers by Specialization

Arginase Inhibition and Cardioprotection in Ischemia/Reperfusion

Study Title: The cardioprotective effects of (-)-Epicatechin are mediated through arginase activity inhibition in a murine model of ischemia/reperfusion

Citation: Ortiz-Vilchis et al., 2018 · European Journal of Pharmacology

What the Study Found: In a murine ischemia/reperfusion model, (−)-epicatechin reduced infarct size by inhibiting arginase activity. This preserved nitric oxide bioavailability, limited oxidative damage, and protected mitochondrial structure during reperfusion stress.

What this means in real life: When a heart attack hits, mitochondria swell and rupture, expanding the damaged zone and robbing cells of energy. This study shows that (−)-epicatechin protects the heart by blocking arginase, keeping nitric oxide high and mitochondria intact. Supporting mitochondrial health is therefore a powerful way to help the heart withstand sudden stress and recover more effectively.

Related Content

Epicatechin and Heart Protection

Study Title: Intravenous (−)-epicatechin reduces myocardial ischemic injury by protecting mitochondrial function

Citation: Yamazaki et al., 2014. International Journal of Cardiology

What the Study Found: This study found that intravenous (−)-epicatechin reduced myocardial infarct size in a rat ischemia-reperfusion model and helped preserve mitochondrial function during reperfusion. It was associated with improved ATP levels, reduced mitochondrial damage, and better overall cellular energy stability following cardiac injury.

What this means in real life: This study shows that protecting mitochondrial function may play a key role in reducing damage after a cardiac event. It highlights that recovery is not just about restoring blood flow, but also about how well cells regain their ability to produce energy.

Related Content:

Epicatechin and Ischemia-Reperfusion Injury

Study Title: (−)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans

Citation: Yamazaki et al., 2008. American Journal of Physiology-Heart and Circulatory Physiology

What the Study Found: This study examined whether oral (−)-epicatechin pretreatment could reduce myocardial ischemia-reperfusion injury in rats. After 10 days of treatment, infarct size was significantly reduced, oxidative stress was lower, MMP-9 activity was more limited in the infarct region, and heart structure remained better preserved over time.

What this means in real life: This study suggests that mitochondrial and tissue protection during reperfusion may be just as important as restoring blood flow itself. It reinforces the idea that reducing oxidative stress and preserving cellular function can influence how much heart damage remains after an ischemic event.

Related Content:

Cacao By-Products, Obesity, and Cardiometabolic Risk

Study Title: Obesity and Cardiovascular Risk Improvement Using Cacao By-Products in a Diet-Induced Obesity Murine Model

Citation: Hidalgo et al., 2019. Journal of Medicinal Food

What the Study Found: This study tested products made from cacao by-products in a rat model of obesity induced by a high-fat diet and fructose intake. The treatments significantly reduced body weight, systolic blood pressure, triglycerides, total cholesterol, LDL cholesterol, and the triglyceride-to-HDL ratio, suggesting broad improvements in cardiometabolic risk markers.

What this means in real life: This study suggests that cacao-derived compounds may support metabolic health beyond cocoa beans themselves, including effects on weight, blood lipids, and blood pressure. It also reinforces the idea that cardiometabolic risk is tied closely to how the body manages energy, fat storage, and vascular stress.

Related Content:

Epicatechin, Obesity, and Cardiometabolic Risk

Study Title: Effects of (−)-epicatechin on a diet-induced rat model of cardiometabolic risk factors

Citation: Gutiérrez-Salmeán et al., 2014. European Journal of Pharmacology

What the Study Found: This study used a high-fat diet rat model and found that (−)-epicatechin reduced weight gain, blood glucose, triglycerides, and blood pressure. It also restored key mitochondrial-related proteins such as PGC-1α, TFAM, and UCP1, which are involved in energy production and metabolic regulation.

What this means in real life: This study shows that cardiometabolic risk is closely tied to how well mitochondria regulate energy and metabolism. It suggests that improving cellular energy systems may influence weight, blood sugar, and lipid balance at the same time.

Related Content:

(+)-Epicatechin and Cardiometabolic Endpoints

Study Title: A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints

Citation: Moreno-Ulloa et al., 2018. Food & Function

What the Study Found: This pilot study evaluated (+)-epicatechin in healthy and pre-diabetic adults and found a favorable pharmacokinetic and safety profile after single-dose and 7-day dosing. In a mouse model of diet-induced obesity and insulin resistance, (+)-epicatechin dose-dependently improved metabolism-related endpoints including weight gain, glucose, cholesterol, and triglycerides, while (+)-catechin did not show the same effects.

What this means in real life: This study suggests that (+)-epicatechin may influence cardiometabolic health through targeted effects on metabolism rather than broad antioxidant activity alone. It also supports the idea that cellular energy regulation and metabolic signaling are tightly connected to outcomes like blood sugar, lipids, and weight control.

Related Content:

Cardiac Fibrosis in Pre-Heart Failure Model

Study Title: (-)-Epicatechin Ameliorates Cardiac Fibrosis in a Female Rat Model of Pre-Heart Failure with Preserved Ejection Fraction

What the Study Found: In an aged female rat model of pre-HFpEF, (−)-epicatechin treatment significantly reduced left ventricular fibrosis. It also lowered plasma oxidative stress markers and levels of profibrotic and proinflammatory cytokines. No detectable changes in left ventricular contractile function were observed.

What this means in real life: In early heart failure, mitochondria in cardiac tissue become stressed, driving fibrosis and inflammation that stiffen the heart. This study shows that (−)-epicatechin can powerfully reduce fibrosis and systemic oxidative/inflammatory load even when ejection fraction is still preserved. Supporting mitochondrial health helps protect the heart from the stiffening process that quietly robs it of efficient energy production.

Related Content

Cocoa Flavanols and Cardiovascular Event Prevention

Study Title: Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

Citation: Manson et al., 2022 · American Journal of Clinical Nutrition

What the Study Found: In a large randomized trial, cocoa flavanol supplementation (containing high levels of (−)-epicatechin) significantly reduced total cardiovascular events compared with placebo. It lowered the composite endpoint of myocardial infarction, stroke, and cardiovascular death. The effect was independent of the multivitamin arm of the study.

What this means in real life: Cardiovascular events often begin with mitochondrial dysfunction in the vascular wall and heart muscle, leading to oxidative damage and inflammation. This landmark trial demonstrates that consistent (−)-epicatechin/flavanol intake can meaningfully lower the risk of major heart events. Mitochondrial support through flavanols is therefore a practical, evidence-based strategy for protecting long-term cardiovascular energy and resilience.

Related Content

Cardiac Fibrosis, High Glucose, and Antifibrotic Protection

Study Title: Antifibrotic Effects of (-)-Epicatechin on High Glucose Stimulated Cardiac Fibroblasts

Citation: Garate-Carrillo et al., 2021 · Journal of Medicinal Food

What the Study Found: High glucose exposure dramatically increased profibrotic markers (TGF-β1, fibronectin, collagen, proline, and urea) in cardiac fibroblasts. Treatment with 1 μM (−)-epicatechin completely blocked these increases. The antifibrotic effect was linked to restoration of GPER levels, c-Src activation, and normalization of SMAD signaling.

What this means in real life: When mitochondria in heart cells face high-glucose stress, they drive excessive fibrosis that stiffens tissue and impairs function. This study shows that (−)-epicatechin directly interrupts that fibrotic cascade at the cellular level, protecting the heart’s structural integrity. Mitochondrial support helps keep cardiac cells from shifting into a stressed, fibrotic state, preserving energy production and long-term heart health.

Related Content

Epicatechin, Endothelial Nitric Oxide, and Mitochondrial Recovery in Simulated Diabetes

Study Title: (-)-Epicatechin-induced recovery of mitochondria from simulated diabetes: Potential role of endothelial nitric oxide synthase

Citation: Ramírez-Sánchez et al., 2016 · Diabetes and Vascular Disease Research

What the Study Found: This study used endothelial cells exposed to high-glucose and high-palmitate conditions to simulate aspects of a diabetic metabolic environment. The researchers reported that these conditions disrupted mitochondrial structure, reduced mitochondrial-related protein markers, and increased oxidative stress. Treatment with (-)-epicatechin helped restore mitochondrial protein markers, improved mitochondrial morphology, and reduced oxidative stress indicators. The study also found that blocking endothelial nitric oxide synthase reduced several of these benefits, suggesting that eNOS-related nitric oxide signaling may be involved in the mitochondrial recovery response.

What this means in real life: This study supports the idea that vascular cells under metabolic stress may lose mitochondrial quality and redox balance, and that (-)-epicatechin may influence pathways connected to mitochondrial recovery. The findings are mechanistic and preclinical, so they should not be interpreted as evidence that (-)-epicatechin treats diabetes or vascular disease in humans. The practical takeaway is narrower: endothelial mitochondrial function, oxidative stress, and nitric oxide signaling appear closely connected in this model of metabolic stress.

Clinical Relevance: Cell study, simulated diabetic endothelial stress model, mitochondrial recovery, oxidative stress, and eNOS-related nitric oxide signaling.

Related Content:

Continue Exploring Mitochondrial Science